The current landscape of frontline DLBCL trials

Advancements in the DLBCL treatment landscapeПодробнее

The current immunotherapeutic landscape for treatment of DLBCLПодробнее

Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusionПодробнее

Current treatment landscape of DLBCLПодробнее

Dr. Martin on the Frontline Treatment Landscape of MCLПодробнее

The current approaches to treating DLBCL in the frontline and relapsed settingsПодробнее

POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalkПодробнее

The current landscape of antibody-based therapies in R/R DLBCLПодробнее

Dr Nowakowski on the Current Treatment Landscape for DLBCLПодробнее

Treating relapsed lymphoma - General Landscape with Dr Michael DickinsonПодробнее

Debate: How should patients with ABC type DLBCL be treated today? - R-CHOPПодробнее

Updates in the DLBCL treatment landscapeПодробнее

Can we improve on R-CHOP for the frontline treatment of DLBCL?Подробнее

Dr. Leslie on the Current Frontline Treatment Landscape in MCLПодробнее

First report of Phase 3 ROBUST trial: R2-CHOP for frontline DLBCLПодробнее

Is frontline R-CHOP still the standard of care for DLBCL?Подробнее

Insights into the ZUMA-23 trial: axi-cel in frontline high-risk LBCLПодробнее

The Polarix Trial: Initial Therapy of Diffuse Large B-cell LymphomaПодробнее

How the treatment landscape of DLBCL is changing: R-CHOP vs pola-R-CHPПодробнее